Contemporary discussions of depression treatment commonly focus on pharmacological approaches, even when the depression occurs during pregnancy. The trend appears to be an emphasis on the dangers of untreated depression and a rush to reassure physicians about the safety of pharmacological agents during pregnancy. While initial findings offer some basis for this reassurance, much remains unknown. Data concerning long-term outcomes, particularly for behavioral teratogenicity, are lacking. The quantity and quality of research on this issue (relying upon animal models, pharmaceutical company-sponsored projects, case reports, retrospective studies, and studies lacking control groups) suggests the need for an open mind about optimal treatment during pregnancy.